Amgen to Acquire Chemocentryx for $4 Billion in Cash

Acquisition Includes TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Serious Autoimmune Disease Tavneos Adds to Amgen's Decades-Long Leadership in Inflammation and Nephrology THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4,... Biopharmaceuticals, Mergers & Acquisitions Amgen, ChemoCentryx, TAVNEOS
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news